Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial: 达格列净治疗接受二甲双胍治疗失败的 …

W Yang, P Han, KW Min, B Wang… - Journal of …, 2016 - Wiley Online Library
摘要背景: 达格列净是一种高选择性的钠‐葡萄糖共转运体2 抑制剂, 可降低2
型糖尿病患者的血糖, 体重和血压. 方法: 这项为期24 周的随机双盲安慰剂对照平行组试验考察 …
被引用次数：62 相关文章

Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.

W Yang, P Han, KW Min, B Wang… - Journal of …, 2016 - search.ebscohost.com
Background: Dapagliflozin, a highly selective sodium–glucose cotransporter 2 inhibitor,
reduces hyperglycemia, body weight, and blood pressure in patients with type 2 diabetes …

Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial

W Yang, P Han, KW Min, B Wang… - Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Dapagliflozin, a highly selective sodium-glucose cotransporter 2 inhibitor,
reduces hyperglycemia, body weight, and blood pressure in patients with type 2 diabetes …

Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial

W Yang, P Han, KW Min, B Wang, T Mansfield… - Journal of …, 2016 - infona.pl
Background Dapagliflozin, a highly selective sodium–glucose cotransporter 2 inhibitor,
reduces hyperglycemia, body weight, and blood pressure in patients with type 2 diabetes …

Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.

W Yang, P Han, KW Min, B Wang, T Mansfield… - Journal of …, 2016 - europepmc.org
Background Dapagliflozin, a highly selective sodium-glucose cotransporter 2 inhibitor,
reduces hyperglycemia, body weight, and blood pressure in patients with type 2 diabetes …